“Efficacy of Tildrakizumab 200 Mg for Treating Difficult-to-Treat Patient Populations With Moderate-to-Severe Plaque Psoriasis”. Dermatology Reports, vol. 17, no. 1, Aug. 2024, https://doi.org/10.4081/dr.2024.9999.